» Articles » PMID: 17136969

The MCID of the Transition Dyspnea Index is a Total Score of One Unit

Overview
Journal COPD
Publisher Informa Healthcare
Specialty Pulmonary Medicine
Date 2006 Dec 2
PMID 17136969
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

The Baseline (BDI) and Transition (TDI) Dyspnea Indexes provide interview-based measurements of breathlessness related to activities of daily living. The BDI is a discriminative instrument that includes specific criteria for each of three components at a single point in time. The TDI is an evaluative instrument that includes specific criteria for each of three components to measure changes from a baseline state. Observational studies have shown that patients with COPD generally experience a gradual progression of breathing difficulty as measured by the TDI over time. Randomized controlled trials have demonstrated excellent measurement characteristics of the TDI; these include responsiveness (ability to detect change) and construct validity (a change in the TDI correlates with changes in other variables). Supporting evidence for one unit as the minimal clinically important difference (MCID) of the TDI is based on: expert preference; use of the physician's global evaluation score as an anchor; and distribution estimates (standard error of measurement and 0.5 of the standard deviation). As an alternative to the interview process, self-administered computerized (SAC) versions of the BDI/TDI have been developed to provide direct patient-reported ratings of dyspnea. To further establish the MCID of the interview-administered and/or the SAC TDI, we recommend that a patient's report of global ratings of change by used as an independent standard or anchor.

Citing Articles

The effectiveness and value of ensifentrine for the treatment of chronic obstructive pulmonary disease.

Wright A, Lin G, Whittington M, McKenna A, Raymond F, Rind D J Manag Care Spec Pharm. 2024; 30(11):1338-1342.

PMID: 39471267 PMC: 11522443. DOI: 10.18553/jmcp.2024.30.11.1338.


Effects of inspiratory muscle training on exertional breathlessness in patients with unilateral diaphragm dysfunction: a randomised trial.

Schaeffer M, Louvaris Z, Rodrigues A, Poddighe D, Gayan-Ramirez G, Gojevic T ERJ Open Res. 2023; 9(5).

PMID: 37868146 PMC: 10588797. DOI: 10.1183/23120541.00300-2023.


Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease.

Meng W, Zeng H, Zhao Z, Xiong R, Chen Y, Li Z Sci Rep. 2023; 13(1):16954.

PMID: 37805617 PMC: 10560244. DOI: 10.1038/s41598-023-44188-2.


How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?.

Kerwin E, Jones P, Bjermer L, Maltais F, Boucot I, Naya I Chron Respir Dis. 2023; 20:14799731231202257.

PMID: 37800633 PMC: 10903204. DOI: 10.1177/14799731231202257.


Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline.

Rochester C, Alison J, Carlin B, Jenkins A, Cox N, Bauldoff G Am J Respir Crit Care Med. 2023; 208(4):e7-e26.

PMID: 37581410 PMC: 10449064. DOI: 10.1164/rccm.202306-1066ST.